Psychiatr. praxi. 2015;16(3):101-104

Treatment of generalized anxiety disorder by using of pregabaline

MUDr.Miroslav Hajda, MUDr.Dana Kamarádová, Ph.D., prof.MUDr.Ján Praško Pavlov, CSc.
Klinika psychiatrie, Lékařská fakulta Univerzity Palackého a Fakultní nemocnice Olomouc

Generalized anxiety disorder is a quite common psychiatric disorder, affecting approximately 8 % of the population. The disorder is often

under diagnosed, due to its lower detection as the difficulties are often mistaken for a normal fears and worries, or it is misdiagnosed -

most often as a mixed anxiety and depressive disorder or an adaptation disorder. As the correct diagnosis is often omitted, the treatment

is often incorrect as well. Patients tend to seek help of other physicians rather than psychiatrists, therefore they are undiagnosed and

do not receive an adequate treatment. This specific group of patients not infrequently chooses a different ways of „self- treatment“,

leading to abuse of addictive substances. The following article presents a case report of a patient who suffers from generalized anxiety

disorder with comorbid somatoform disorder and zolpideme abuse. She had been treated by antidepressants without any effect, now

showing a good response to pregabaline and slow gradual reduction of zolpideme.

Keywords: GAD, anxiety, somatoform disorder, zolpideme addiction, pregabaline

Published: December 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hajda M, Kamarádová D, Praško Pavlov J. Treatment of generalized anxiety disorder by using of pregabaline. Psychiatr. praxi. 2015;16(3):101-104.
Download citation

References

  1. Wittchen HU, Hoyer J. Generalized anxiety disorder: nature and course. J Clin Psychiatry 2001; 62(suppl. 11): 15-19.
  2. Kessler RC, DuPont RL, Berglund P, Wittchen HU. Impairment in pure and comorbid generalized anxiety disorder ond major depression at 12 months in two national surveys.; Am JPsychiatry 1999; 156(12): 1915-1923. Go to original source...
  3. Sramek JJ, Zarotsky C, Cutler NR: Generalized anxiety disorder: treatment options. Drugs 2002; 62: 1635-1648. Go to original source... Go to PubMed...
  4. Praško J, Herman E, Hovorka J. (1999). Generalizovaná úzkostná porucha. In: Seifertová D, Praško J, Hőschl C. (eds): Postupy v léčbě psychických poruch. Praha: Academia Medica Pragensis, 2004 c; 175: 192.
  5. Rocca P, Fonzo V, Scotta M, et al. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr. Scand. 1997; 95(5): 444-445. Go to original source... Go to PubMed...
  6. Keller MB, Harrison W, Fawcett JA, et al. Treatment of chronic depression with sertraline or imipramine: Preliminary blinded response rates and high rates of under-treatment in the community. Psychopharmacol Bull 1995; 31(2): 205-212. Go to PubMed...
  7. Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended release capsules in nondepressed outpatients with generalized anxiety disorder. JAMA 2000; 283: 3082-3088. Go to original source... Go to PubMed...
  8. Pollack MH, Bose A, Zheng H. Efficacy and tolerability of escitalopram in the treatment of anxiety disorder. Presented at the 23rd Annual conference of Anxiety disorders Association of America, March 27-30, Toronto 2003.
  9. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. Arch. Gen. Psychiatry 1993; 50: 884-895. Go to original source... Go to PubMed...
  10. Hedges DW, Reimherr FW, Strong RE, Halls CH, Rust C. An open trial of nefazodone in adult patients with generalized anxiety disorder. Psychopharmacol Bull 1996; 32: 671-676. Go to PubMed...
  11. Goodnick PJ, Puig A, DeVane CL, et al. Mirtazapine in major depression with comorbid generalized anxiety disorder. J Clin Psychiatry 1999; 60: 446-448. Go to original source... Go to PubMed...
  12. Plag J, Schumacher S, Ströhle A. Generalized anxiety disorder. Nervenarzt. 2014; 85(9): 1185-1194. Go to original source... Go to PubMed...
  13. Ambler Z. Pregabalin v léčbě neuropatické bolesti. Farmakoterapie 2011; 7[Suppl.]: 49-52.
  14. Bednařík J. Farmakoterapie neuropatické bolesti ve světle medicíny založené na důkazech. Bolest 2014; 17(2): 41-46.
  15. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, Liu-Dumaw M, Carter CM, Pande AC. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23: 240-249. Go to original source... Go to PubMed...
  16. Pande AC, Crockatt JG, Janney C, et al. Three randomized, placebo-controlled double-blind trials of pregabalin treatment of generalized anxiety disorder (GAD) (abstract no. P.3.025) Int J Neuropsychopharmacol 2000; 3(suppl 1): S344. Go to original source...
  17. Pohl RB, Feltner DE, Fieve RR, et al. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005; 25: 151-158. Go to original source... Go to PubMed...
  18. Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005; 62: 1022-1030. Go to original source... Go to PubMed...
  19. Montgomery SA, Tobias K, Zornberg GL, et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006; 67: 771-782. Go to original source... Go to PubMed...
  20. Smith W, Feltner D, Kavoussi R. Pregabalin in generalized anxiety disorder: long term efficacy and relapse prevention (abstract no. P.3.047). Eur Neuropsychopharmacol 2002; 12(suppl. 3): S350. Go to original source...
  21. Mula M. Treatment of anxiety disorders in epilepsy: an evidence-based approach. Epilepsia. 2013; 54(1): 13-18. Go to original source... Go to PubMed...
  22. Kawalec P, Cierniak A, Pilc A, Nowak G. Pregabalin for the treatment of social anxiety disorder. Expert Opin Investig Drugs. 2015; 24(4): 585-594. Go to original source... Go to PubMed...
  23. Baniasadi M, Hosseini G, Fayyazi Bordbar MR, Rezaei Ardani A, Mostafavi Toroghi H. Effect of pregabalin augmentation in treatment of patients with combat-related chronic posttraumatic stress disorder: a randomized controlled trial. J Psychiatr Pract. 2014; 20(6): 419-427. Go to original source... Go to PubMed...
  24. Englisch S, Esser A, Enning F, Hohmann S, Schanz H, Zink M. Augmentation with pregabalin in schizophrenia. J Clin Psychopharmacol. 2010; 30(4): 437-440. Go to original source... Go to PubMed...
  25. Cvjetkovic-Bosnjak M, Soldatovic-Stajic B, Babovic SS, Boskovic K, Jovicevic M. Pregabalin versus sertraline in generalized anxiety disorder. An open label study. Eur Rev Med Pharmacol Sci. 2015; 19(11): 2120-2124. Go to PubMed...
  26. Olivares JM, Álvarez E, Carrasco JL, Pérez Páramo M, López-Gómez V. Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms. Int Clin Psychopharmacol. 2015; 30(5): 265-271. Go to original source... Go to PubMed...
  27. Álvarez E, Olivares JM, Carrasco JL, López-Gómez V, Rejas J. Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors. Ann Gen Psychiatry. 2015 Jan 22; 14(1): 2. Go to original source... Go to PubMed...
  28. Montgomery S, Emir B, Haswell H, Prieto R. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability. Curr Med Res Opin. 2013; 29(10): 1223-1230. Go to original source... Go to PubMed...
  29. Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs. 2014; 28(9): 835-854. Go to original source... Go to PubMed...
  30. Ruiz MA, Álvarez E, Carrasco JL, Olivares JM, Pérez M, Rejas J. Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice. Drug Des Devel Ther. 2015; 9: 4329-4340. Go to original source... Go to PubMed...
  31. Roth T, Arnold LM, Garcia-Borreguero D, Resnick M, Clair AG. A review of the effects of pregabalin on sleep disturbance across multiple clinical conditions. Sleep Med Rev. 2014; 18(3): 261-271. Go to original source... Go to PubMed...
  32. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders - First Revision. World Journal of Biological Psychiatry 2008; 9(4): 248-312. Go to original source... Go to PubMed...
  33. Sabioni P, Bertram J, Le Foll B. Off-Label Use of Medications for Treatment of Benzodiazepine Use Disorder. Curr Pharm Des. 2015; 21(23): 3306-3310. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.